{"entity":{"id":"nct07713290","kind":"trial","name":"A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma","aka":[],"tldr":"A phase 1 trial of GKL-006 Injection run by Beijing Gene Key Life Technology Co., Ltd, active and no longer recruiting.","summary":"A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma is a phase 1 interventional study registered as NCT07713290 by Beijing Gene Key Life Technology Co., Ltd, with 6 participants planned, started 2025-04-03. Conditions recorded: Hepatocellular Carcinoma (HCC) and Unresectable Hepatocellular Cancer. Interventions recorded: GKL-006 Injection and Transarterial chemoembolization (TACE).","status":"active","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07713290","url":"https://clinicaltrials.gov/study/NCT07713290"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["gkl-006"],"companies":["beijing-gene-key-life-technology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07713290","phase":"1","setting":"An Open-Label, Multiple-Dose Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma","sponsor":"Beijing Gene Key Life Technology Co., Ltd","enrolled":6,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07713290/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"gkl-006","kind":"drug","name":"GKL-006 Injection","route":"/drugs/gkl-006/"}],"company":[{"id":"beijing-gene-key-life-technology","kind":"company","name":"Beijing Gene Key Life Technology","route":"/companies/beijing-gene-key-life-technology/"}]}}